Corporate DealsSep 15, 2025 · 7:00am ET
GLUEMonte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Collaboration with Novartis for Immune-Mediated Disease Degraders
Deal includes $120 million upfront and up to $5.7 billion in total value.
Corporate DealsSep 15, 2025 · 7:00am ET
GLUEMonte Rosa Therapeutics, Inc.+79.8%
Monte Rosa Therapeutics Announces Collaboration with Novartis for Immune-Mediated Disease Degraders